Hims & Hers shares slid nearly 40% after losing a partnership with Novo Nordisk and facing scrutiny over compounded GLP-1 drugs competing with therapies from Novo and Eli Lilly. Analysts mostly rate the stock a hold, viewing the slowdown as cooling growth rather than structural damage.